Form 4 for SGMT Sagimet Biosciences Inc.
Accepted 2025-02-07 00:00:00 ET · period of report 2025-02-06 · accession 0001104659-25-010589 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-07 | 2025-02-06 | SGMT | Martins Eduardo Bruno | Chief Medical Off | A - Grant | $0.00 | +34.0K | 115.2K | +42% | $0 |
| D | 2025-02-07 | 2025-02-06 | SGMT | Martins Eduardo Bruno | Chief Medical Off | A - Grant | $0.00 | +138.0K | 138.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Series A Common Stock | 2025-02-06 | A | A | 34,000 | $0.00 | 115,213 | D | — | — | (F1) Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-02-06 | A | A | 138,000 | $0.00 | 138,000 | D | $4.71 · — to 2035-02-05 | 138,000 Series A Common Stock | (F2) The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date. |